Skip to main content

Table 6 Efficacy of first-line treatment and second-line treatment in lenvatinib monotreatment group

From: Efficacy and safety of lenvatinib monotreatment and lenvatinib-based combination therapy for patients with unresectable hepatocellular carcinoma: a retrospective, real-world study in China

LEN (n = 39) First-line treatment (n = 27) Second-line treatment (n = 12)
CR 0 0
PR 5 1
SD 12 9
PD 10 2
ORR 19% 8%
DCR 63% 83%
  1. LEN, lenvatinib; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; DCR, disease control rate